Revenue: Not reported (null) for QQ4 2024; no QoQ or YoY revenue data available.
Gross Profit: -$5,764 for QQ4 2024; Gross Profit Margin not meaningful as revenue is null.
Operating Income: -$259,899 in QQ4 2024; YoY change -23.76%; QoQ change +38.25% (as reported in the ratios data).
Net Income: -$358,578 in QQ4 2024; YoY change +52.06%; QoQ change +31.92% (as reported).
Earnings Per Share (EPS): -$95.95 (both basic and diluted); YoY and QoQ percentages shown as -73,707.69% and +67.67% respectively in the data.
EBITDA: -$263,047 in QQ4 2024.
Cash Flow and Liquidity:
- Net cash provided by operating activities: -$259,966.
- Net change in cash: +$14,863; cash at end of period: $21,085; cash at beginning of period: $6,222.
- Free cash flow: -$259,966 (equivalent to CFO given no capex in the period).
Balance Sheet Highlights:
- Total assets: $72,365; cash and cash equivalents: $21,085; total current assets: $25,441; net property, plant & equipment: $17,799; non-current assets: $46,924.
- Total liabilities: $3,851,424; total current liabilities: $3,792,782; short-term debt: $889,629; long-term debt: $58,642; total debt: $948,271; net debt: $927,186.
- Total stockholders’ equity: -$3,779,059; accumulated deficit indicates ongoing cumulative losses.
- Liquidity ratios: current ratio 0.0067; quick ratio 0.0067; cash ratio 0.0056; cash conversion and days payables indicate an elevated working capital risk.
Notes: The figures reflect a biotech microcap in preclinical development with no reported revenue in QQ4 2024 and substantial reliance on external financing to fund ongoing burn. The reported yoy and qoq percentage changes for profitability metrics are provided in the dataset, but may be distorted by negative bases and non-operating items. The earnings transcript in the data is empty, so management commentary and forward guidance via call quotes are not available in this dataset.